Purification of immunoglobulins

a technology of immunoglobulin and purification method, which is applied in the field of antibody preparation, can solve the problems of time-consuming and laborious, impure products, and difficult to use the supernatant for other purposes

Active Publication Date: 2006-06-22
CYTIVA BIOPROCESS R&D AB
View PDF7 Cites 100 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013] However, despite the state of the art constructions, there is still a need of alternative separation matrices for purification of antibodies or antibody constructs, which observe the demands of purity, safety, potency and cost effectiveness.

Problems solved by technology

Typically, these precipitation methods are giving very impure products while at the same time being time consuming and laborious.
Furthermore, the addition of the precipitating agent to the raw material makes it difficult to use the supernatant for other purposes and creates a disposal problem, which is particularly relevant when speaking of large-scale purification of immunoglobulins.
Thus, a disadvantage of this procedure is the necessity to add lyotropic salt to the raw material as this gives and problem and thereby increased cost to the large-scale user.
For other raw materials than cell culture supernatants such as whey, plasma, and egg yolk the addition of lyotropic salts to the raw materials would in many instances be prohibitive in large-scale applications as the salt could prevent any economically feasible use of the immunoglobulin depleted raw material.
An additional problem in large-scale applications would be the disposal of several thousand litres of waste.
Although the matrices described for thiophilic chromatography generally show good performance, since lyotropic salts are added to the raw material to ensure efficient binding of the immunoglobulin, disadvantages as discussed above will arise.
However, despite the state of the art constructions, there is still a need of alternative separation matrices for purification of antibodies or antibody constructs, which observe the demands of purity, safety, potency and cost effectiveness.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purification of immunoglobulins
  • Purification of immunoglobulins

Examples

Experimental program
Comparison scheme
Effect test

example 1

n Matrices

[0049] Agarose particles were prepared by suspension gelation as disclosed in U.S. Pat. No. 6,602,990 (Amersham Biosciences). More specifically, particles having a Kav of 0.69 were produced by the appropriate adjustment of solids content, according to well known principles in this field. Further, by adjusting the speed and duration of stirring, the median particle diameter was controlled to 80 μm.

[0050] The particles described above were epoxi-activated and recombinant Protein A (rprotein A) was coupled to the particles via C-terminal, following well known procedures as described e.g. in Hermanson, Greg T., Mallia, A. Krishna, Smith, Paul K. Immobilized Affinity Ligand Techniques, p. 118. Academic Press. ISBN 0-12-342330-9. The rProtein A ligands were coupled to a ligand density of 7.3 mg / ml.

[0051] The comparative separation matrix was MabSelect™, obtained from Amersham Biosciences, which according to the product note presents a median particle size of the cumulative vol...

example 2

inding Capacity

[0052] The dynamic binding capacity (DBC) of the separation matrix prepared as described in Example 1 was tested as follows: Human polyclonal IgG was loaded, 1.0 mg / ml at neutral pH onto two columns packed with the product. The capacity is determined at 10% breakthrough, and the results are shown in FIG. 1.

[0053] Equipment

Packing of columnsColumns (2)XK16 / 20Amersham BiosciencesPacking reservoirXK16 / 20Amersham BiosciencesPump25 ml / minute, e.g. P-900Amersham BiosciencesRelief valve0.3 MPaAmersham BiosciencesPressure meter

Chromatography

[0054]ÄKTA™ Explorer 10 or AKTA FPLC™ (Amersham Biosciences) Spectrophotometer, double beam

ChemicalsEthanol99.5%Spectroph.Sodium Chloridep aSodium Dihydrogenp aBakerM = 137.99 g / molPhosph.Sodium Hydroxidep aProlaboM = 40.00 g / molSodium Citratep aMerckM = 75.07 g / molHydrochloric acidp aGammanorm165 mg / mlOctapharma

Solutions

[0055] Buffers

Packing solution 1:20% (v / v) ethanol containing 0.25 M NaCl.Packing solution 2:20% (v / v) ethano...

example 3

on of the Gel Phase Distribution Coefficient

Principle

[0067] The gel phase distribution coefficient of a particle according to example 1 is determined by gel filtration. Two dextrans with different sizes are run through a packed HR16 / 30 column. Retention volumes for each dextran are detected, and used to calculate Kav, a value describing the fraction of the particle volume available for a certain molecular weight. From the Kav-values the Kav-value for Mp 110000 is reported.

[0068] Equipment

PackingColumnHR 16 / 30Packing tubeHR 16 / 30PumpÄKTA ™ P-900 pump or equal

[0069] Selectivity test

ÄKTA explorer 10 System or equalControlUNICORN ™Sample InjectionAutosampler A-900*Sample loop200 μlPumpsP-900DetectorShimadzu RI-detector

Chemicals

[0070] Mobile phase for packing is distilled water and for the selectivity test 0.20 M NaCl in distilled water.

[0071] The column packing is tested with an injection of 2% acetone in a distilled water mobile phase.

[0072] The dextrans used in the selectiv...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
densityaaaaaaaaaa
median particle diameteraaaaaaaaaa
median particle diameteraaaaaaaaaa
Login to view more

Abstract

The present invention relates to a separation matrix comprised of porous particles to which antibody-binding protein ligands have been immobilised, wherein the ligand density is in the range of 5.0-10 mg/ml; the gel phase distribution coefficient of the particles expressed as Kav for a dextran of size 110 kDa is above 0.65 and the median particle diameter is between 65-84 μm. The carbohydrate material is preferably highly cross-linked agarose.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. provisional patent application number 60 / 638,316 filed Dec. 22, 2004; the entire disclosure of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to the field of antibody preparation, and more specifically to a separation matrix for isolation and / or separation of antibodies. The invention also encompasses a chromatography column that comprises the separation matrix of the invention, a method of isolating antibodies using said separation matrix and a multistep process for large-scale purification of antibodies from a crude feed. BACKGROUND OF THE INVENTION [0003] The immune system is composed of many interdependent cell types that collectively protect the body from bacterial, parasitic, fungal, viral infections and from the growth of tumour cells. The guards of the immune system are macrophages that continually roam the bloodstream...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/558
CPCG01N33/558B01D15/3809B01J20/286B01J20/3212B01J20/3274G01N33/543Y10S436/824
Inventor BERG, HANSMALMQUIST, GUNNARABERG, PER-MIKAELJOHANSSON, HANS
Owner CYTIVA BIOPROCESS R&D AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products